MDM2 SNP309 and cancer risk: A combined analysis

Carcinogenesis

Volumn 28, Issue 11, 2007, Pages 2262-2267

  Wilkening, Stefan ^a   Bermejo, Justo Lorenzo ^a   Hemminki, Kari ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CARCINOMA; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INTRON; LIVER CELL CARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; NASOPHARYNX CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOMA;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; GENE FREQUENCY; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS;

EID: 36248995926     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm191     Document Type: Article

References (50)

1. Momand,J. et al. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
2. Michael,D. et al. (2003) The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol., 13, 49-58.
3. Zhang,Z. et al. (2005) p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets, 5 9-20.
4. Bond,G.L. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
5. Bond,G.L. et al. (2005) A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res., 65, 5481-5484.
6. Ries,S. et al. (2000) Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell, 103, 321-330.
7. Zauberman,A. et al. (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 23, 2584-2592.
8. Arva,N.C. et al. (2005) A chromatin-associated and transcriptionally in-active p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem., 280, 26776-26787.
9. Hu,W. et al. (2007) A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res., 67, 2757-2765.
10. Jun,H.J. et al. (2007) Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol. Carcinog., 46 100-105.
11. Park,S.H. et al. (2006) MDM2 309TG polymorphism. and risk of lung cancer in a Korean population. Lung Cancer, 54, 19-24.
12. Higgins,J.P., Thompson,S.G. et al. (2002) Quantifying heterogeneity in a meta-analysis. Stat. Med., 21, 1539-1558.
13. Bond,G.L. et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res., 66 5104-5110.
14. Wasielewski,M. et al. (2007) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res. Treat., 104, 153-157.
15. Campbell,I.G. et al. (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett., 240, 195-197.
16. Copson,E.R. et al. (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer, 6, 80.
17. Ma,H. et al. (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population. Cancer Lett., 240, 261-267.
18. Millikan,R.C. et al. (2006) No association between the MDM2 - 309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol. Biomarkers Prev., 15, 175-177.
19. Wilkening,S. et al. (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res., 66, 646-648.
20. Boersma,B.J. et al. (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J. Natl Cancer Inst., 98 911-919.
21. Petenkaya,A. et al. (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res., 26, 4975-4977.
22. Cox,D.G. et al. (2007) The p53 Arg72Pro and MDM2 - 309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control, 18, 621-625.
23. Alhopuro,P. et al. (2005) The MDM2 promoter polymorphism SNP309T-G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med. Genet., 42, 694-698.
24. Menin,C. et al. (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J. Natl Cancer Inst., 98, 285-288.
25. Sotamaa,K. et al. (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res., 11, 6840-6844.
26. Talseth,B.A. et al. (2007) MDM2 SNP309 TG alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int. J. Cancer, 120, 563-565.
27. Bond,G.L. et al. (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J. Med. Genet., 43, 950-952.
28. Alazzouzi,H. et al. (2007) Tumour selection advantage of non-dominant negative p53 mutations in homozygous mdm2-snp309 colorectal cancer cells. J. Med. Genet., 44, 75-80.
29. Lind,H. et al. (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer, 119, 718-721.
30. Zhang,X. et al. (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat., 27, 110-117.
31. Li,G. et al. (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: A case-control analysis. Carcinogenesis, 27, 2028-2033.
32. Hu,Z. et al. (2006) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer, 118, 1275-1278.
33. Pine,S.R. et al. (2006) MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 15 1559-1561.
34. Ohmiya,N. et al. (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol., 24, 4434-4440.
35. Onat,O.E. et al. (2006) MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res., 26, 3473-3475.
36. Hong,Y. et al. (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res., 65 9582-9587.
37. Dharel,N. et al. (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin. Cancer Res., 12, 4867-4871.
38. Walsh,C.S. et al. (2007) Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol. Oncol., 104, 660-664.
39. Swinney,R.M. et al. (2005) MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia, 19, 1996-1998.
40. Garg,R. et al. (2006) Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol. Oncol., 103, 793-796.
41. Zhou,G. et al. (2007) MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin. Cancer Res., 13, 2627-2633.
42. Wilkening,S. et al. (2007) No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol, 157, 375-177.
43. Toyama,T. et al. (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res., 9, R34.
44. Ruijs,M.W. et al. (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur. J. Hum. Genet., 15, 110-114.
45. Bougeard,G. et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet., 43, 531-533.
46. Heist,R.S. et al. (2006) Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin. Cancer Res. 12, 5448-5453.
47. Harris,S.L. et al. (2005) Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc. Natl Acad. Sci. USA, 102, 16297-16302.
48. Bond,G.L. et al. (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene, 26, 1317-1323.
49. Houlston,R.S. et al. (2003) The future of association studies of common cancers. Hum. Genet., 112, 434-435.
50. Antoniou,A.C. et al. (2003) Polygenic inheritance of breast cancer: Implications for design of association studies. Genet. Epidemiol., 25, 190-202.